HAEMONETICS CORP financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data HAEMONETICS CORP files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	886	904	968	988	870	993	1,169	1,309	1,361	1,334
Cost of revenue	508	492	550	504	473	488	554	618	612	546
Gross profit	378	412	418	485	398	506	615	692	749	788
Research and development	37.6	39.2	35.7	30.9	32.9	46.8	50.1	54.4	62.7	59.8
Selling, general and administrative	302	317	273	282	275	340	377	430	437	442
Operating expenses	398	356	334	381	308	425	459	527	527	631
Operating income	-19.4	56.2	83.5	103	89.7	80.8	156	165	222	157
Interest expense		7.7	12.6	13.5	9.4	5.8	13	19.5	35.9	19.3
Other non-operating income	-8.1	-4.53	-9.91	-16.2	-16.8	-17.1	-14.6	-13	-9.75	-28.7
Pre-tax income	-27.5	59.6	73.6	87.2	72.9	63.6	141	152	212	128
Income tax	-1.21	14.1	18.6	10.6	-6.56	20.3	26	34.3	44.4	30.7
Net income	-26.3	45.6	55	76.5	79.5	43.4	115	118	168	97.3
EBITDA	70.4	145	193	214	174	178	249	262	337	268
EPS, basic	-0.51	0.86	1.07	1.51	1.57	0.85	2.27	2.32	3.33	2.06
EPS, diluted	-0.51	0.85	1.04	1.48	1.55	0.84	2.24	2.29	3.31	2.05
Shares, basic (weighted)	51.5	52.8	51.5	50.7	50.7	51	50.8	50.7	50.3	47.2
Shares, diluted (weighted)	51.5	53.5	52.9	51.8	51.3	51.4	51.4	51.4	50.7	47.4

Balance sheet

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cash and equivalents	140	180	169	137	192	259	284	179	307	245
Receivables	153	151	185	165	128	159	179	207	203	217
Inventory	177	161	194	270	323	293	259	317	365	306
Other current assets	40.9	29	27.4	30.8	51.1	44.1	46.7	66.3	60.4	66.2
Total current assets	510	521	576	604	694	756	770	769	935	835
Property, plant and equipment	324	332	344	253	218	258	311	311	284	306
Lease right-of-use assets				52.2	59.9	52.7	53.4	55.3	47.5	39.6
Goodwill	211	211	211	211	466	467	466	565	604	656
Intangible assets	178	157	128	133	365	310	276	406	456	448
Other non-current assets	12.4	12.1	11.8	62.4	70.9	63.2	107	136	164	142
Total assets	1,239	1,237	1,275	1,267	1,820	1,860	1,935	2,196	2,451	2,396
Accounts payable	43	55.3	63.4	50.7	50.3	58.4	63.9	73.4	67	51.1
Accrued liabilities	43.5	69.5	53.2	49.5	47.6	48.5	64.5	80.7	59.4	68.2
Deferred revenue	26.5	25.8	27.3	28.8	26.3	26.8	30.2	31.2	43.3	42.3
Short-term debt	61	194	27.7	77	17	214	11.8	10.2	304	5.02
Total current liabilities	211	385	236	275	253	442	252	300	578	283
Long-term debt	254	59.4	322	306	691	559	754	798	921	1,220
Lease liabilities				52	63	55.7	55.9	58	50.5	40.9
Other non-current liabilities	22.2	34.3	28.8	89.1	100	79.9	74.7	75	68.2	59.4
Total liabilities	499	485	607	680	1,088	1,110	1,117	1,236	1,630	1,600
Total debt	316	254	350	382	708	774	766	808	1,225	1,240
Paid-in capital	482	504	536	553	603	572	595	635	523	554
Retained earnings	290	267	161	78.5	158	202	253	360	352	279
Other comprehensive income	-32.9	-19	-30.4	-45.1	-29.5	-26	-30.4	-35.6	-55.1	-37.6
Shareholders' equity	740	752	668	587	732	749	818	960	821	796
Total equity	740	752	668	587	732	749	818	960	821	796
Total liabilities and equity	1,239	1,237	1,275	1,267	1,820	1,860	1,935	2,196	2,451	2,396
Shares outstanding	52.3	52.3	51	50.3	50.9	51.1	50.4	50.8	48.2	45.3

Cash flow statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Net income	-26.3	45.6	55	76.5	79.5	43.4	115	118	168	97.3
Depreciation and amortization	89.7	89.2	109	110	84.3	97.7	93.3	97.2	116	112
Stock-based compensation	9.15	13	17.2	20.5	25.5	24.4	25.6	28.3	29.6	33.8
Deferred income tax	-6.8	-5.83	13.4	-6.73	-20.8	5.05	5.78	-10.9	-5.62	-26.4
Change in receivables	3.16	5.09	-38.1	18.9	44.1	-35	-24.4	-24.2	6.96	-14.9
Change in inventory	-1.55	14.4	-39.3	-84.7	-38.9	24.3	30.8	-60.1	-64.7	47.4
Change in payables	21.1	41.4	17.7	-17.3	-56.4	7.64	39.8	44.6	-19.2	-16.6
Cash from operations	160	220	159	158	109	172	273	182	182	293
Capital expenditures	-76.1	-74.8	-119	-48.8	-37	-96.5	-191	-38.1	-39.3	-32.8
Acquisitions					-435	-2.5	-2.85	-244	-151	-60.2
Cash from investing	-73.3	-63	-116	-57.2	-425	-86.3	-144	-322	-162	-180
Debt issued	0	0	348	0
Debt repaid	-42.7	-61.7	-267	-13.1	-21.9	-17.5	-9.63	-12.3	-4.69
Stock issued	29.4	37.1	10.2	8.65	6.22	2.34	2.64	1.61
Share buybacks	0	-100	-160	-175	0	0	-75	0	-225	-175
Cash from financing	-60.4	-121	-50.6	-131	367	-15.7	-100	38.2	109	-178
Exchange rate effect	-1.57	3.94	-3.32	-1.87	4.18	-2.98	-3.94	-3.19	-0.69	3.46
Net change in cash	24.4	40.6	-10.8	-32	55	67.2	25	-106	128	-61.3
Free cash flow	83.6	146	40.3	109	71.8	75.8	81.7	144	142	260
Interest paid	7.85	7.66	13.1	12.5	7.82	6.19	13.6	20.9	16.5	17.5
Income taxes paid	6.96	9.08	8.21	11.5	12.5	24.3	18	52.7	49.3	60.7

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 27, 2026; growth uses fiscal years. Valuation uses the share price of $105.30 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	59.0%	Gross profit / revenue.
Operating margin	11.9%	Operating income / revenue.
EBITDA margin	20.0%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	9.6%	Pre-tax income / revenue.
Net margin	7.1%	Net income / revenue.
FCF margin	21.5%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	24.3%	Cash from operations / revenue.
Effective tax rate	26.2%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	11.5%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	4.1%	Net income / average total assets.
Return on invested capital (ROIC)	6.6%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	4.4%	Research and development expense / revenue.
SG&A / revenue	33.3%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	2.5%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	2.7%	Capital expenditures / revenue.
D&A / revenue	8.1%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-2.0%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	4.5%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	8.9%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	5.2%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	8.6%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	14.6%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-29.3%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	0.1%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	11.8%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	-20.4%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	2.5%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	9.1%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-42.0%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	-5.5%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	4.1%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	-38.1%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	-2.9%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	5.8%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	61.4%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	2.4%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	21.9%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	82.8%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	47.2%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	29.4%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-3.0%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-0.9%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	1.7%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-2.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	7.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	5.7%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-6.7%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-2.7%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-1.6%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	3.08x	Current assets / current liabilities.
Quick ratio	1.67x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.85x	(Cash + short-term investments) / current liabilities.
Debt / equity	1.42x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	50.2%	Total debt / total assets.
Liabilities / assets	64.6%	Total liabilities / total assets.
Net debt	$964.8M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	3.57x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Working capital	$547.6M	Current assets - current liabilities.
Goodwill and intangibles / assets	46.1%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$254.3M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.57x	Revenue / average total assets.
Fixed asset turnover	4.45x	Revenue / average property, plant and equipment.
Inventory turnover	1.81x	Cost of revenue / average inventory.
Days inventory	202 days	365 x average inventory / cost of revenue.
Receivables turnover	6.26x	Revenue / average receivables.
Days sales outstanding	58 days	365 x average receivables / revenue.
Days payables	37 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	223 days	Days inventory + days sales outstanding - days payables.
FCF conversion	302.4%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	11.3%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$2.11	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$29.58	Revenue / diluted weighted shares.
FCF per share	$6.37	Free cash flow / diluted weighted shares.
Operating cash flow per share	$7.18	Cash from operations / diluted weighted shares.
Book value per share	$18.41	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$5.59	Tangible book value / shares outstanding.
Cash per share	$4.91	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$4.79B	Share price x shares outstanding.
Enterprise value	$5.76B	Market cap + total debt - cash - short-term investments.
P/E	49.8x	Market cap / net income. Only when net income is positive.
P/S	3.54x	Market cap / revenue.
P/B	5.72x	Market cap / shareholders' equity. Only when equity is positive.
P/FCF	16.5x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	14.6x	Market cap / cash from operations, when positive.
EV/Sales	4.26x	Enterprise value / revenue.
EV/EBIT	35.9x	Enterprise value / operating income, when both are positive.
EV/EBITDA	21.3x	Enterprise value / EBITDA, when both are positive.
EV/FCF	19.8x	Enterprise value / free cash flow, when both are positive.
FCF yield	6.1%	Free cash flow / market cap.
Earnings yield	2.0%	Net income / market cap (the inverse of P/E).

What was HAEMONETICS CORP's revenue in fiscal 2026?

HAEMONETICS CORP reported revenue of $1.33B for fiscal 2026, 2% lower than the year before.

Was HAEMONETICS CORP profitable in fiscal 2026?

Yes. Net income was $97.3M, a net margin of 7.3%.

How much free cash flow did HAEMONETICS CORP generate in fiscal 2026?

Cash from operations of $293.2M minus capital expenditures of $32.8M left free cash flow of $260.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to HAEMONETICS CORP